At 5.7% CAGR, the Asia Pacific Clinic Casting and Splinting Products Market is projected to be worth US$ 444.44 million by 2030, says Business Market Insights

According to Business Market Insights’ research, the Asia Pacific clinic casting and splinting products market was valued at US$ 284.43 million in 2022 and is expected to reach US$ 444.44 million by 2030, registering a CAGR of 5.7% from 2022 to 2030. Rising prevalence of musculoskeletal conditions and high prevalence of age-related orthopedic disorders are the critical factors attributed to the Asia Pacific clinic casting and splinting products market expansion.        

Arthritis, osteoarthritis, rheumatoid arthritis, bursitis, elbow pain, and fractures are among the most common orthopedic disorders. Among these, arthritis, osteoporosis, and fractures are a few common problems faced by older people. Osteoporosis is one of the most common bone system diseases associated with an increased risk of bone fractures and causes many complications for patients. With age, the prevalence of this disease increases so that it has become a serious problem among the elderly. Rapidly aging population and biological changes in older adults’ bodies mean that orthopedic injuries are increasing. Orthopedic problems are more common among aged men, whereas most aged women reported joints problems. As people age, their bone mineral density decreases. Low mineral density can cause various health concerns to post-menopausal women. Decreased mineral levels result in weak and brittle bones. Older adults can suffer from unsteady balance and vision problems, increasing the risk of fractures. Bone mass peaks at about 30 years of age and starts decreasing with growing age. Reduction in bone mass can increase the risk of osteoporosis in older adults.

According to a study by National Library of Medicine, in 2020, the prevalence of osteoporosis among elders in China was 39.4%. In 2019, the prevalence was 49% in Nepal, 11% in Taiwan, and 7.9% in Iran.

According to the World Health Organization (WHO), osteoporosis is the second disease as a global healthcare problem. Fractures are various common among the elderly population. Due to osteoporosis, 50% of women and up to 25% of men aged 50 years and above may have a facture. According to UN DESA’s Population Division, the number of individuals aged 65 years and above is estimated to increase from 761 million in 2021 to 1.6 billion by 2050. Therefore, the rising prevalence of orthopedic disorders among the aged population propels the demand for casting and splinting products as the casts and splints hold the bones in place while they heal and help reduce pain, swelling, and muscle spasm.

On the contrary, complications related to casting and splinting hamper the Asia Pacific clinic casting and splinting products market. 

Based on product, the Asia Pacific clinic casting and splinting products market is segmented into casting and splinting. The casting segment held 65.6% share of Asia Pacific clinic casting and splinting products market in 2022, amassing US$ 186.50 million. It is projected to garner US$ 285.33 million by 2030 to expand at 5.5% CAGR during 2022–2030. The casting is sub-segmented into casts, tapes, cutters, and casting accessories. The splinting segment is further segmented into splints and splinting accessories.

Based on application, the Asia Pacific clinic casting and splinting products market is segmented into acute fractures or sprains, tendon and ligament injuries, and others. The acute fractures segment held 47.9% share of Asia Pacific clinic casting and splinting products market in 2022, amassing US$ 136.20 million. It is projected to garner US$ 217.70 million by 2030 to expand at 6.0% CAGR during 2022–2030.

Based on material, the Asia Pacific clinic casting and splinting products market is segmented into Plaster of Paris, fiberglass, and others. The Plaster of Paris segment held 46.9% share of Asia Pacific clinic casting and splinting products market in 2022, amassing US$ 133.33 million. It is projected to garner US$ 204.75 million by 2030 to expand at 5.5% CAGR during 2022–2030.

Based on country, the Asia Pacific clinic casting and splinting products market has been categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 35.7% share of Asia Pacific clinic casting and splinting products market in 2022. It was assessed at US$ 101.51 million in 2022 and is likely to hit US$ 161.82 million by 2030, exhibiting a CAGR of 6.0% during 2022–2030.      

Key players operating in the Asia Pacific clinic casting and splinting products market are 3M Co, DeRoyal Industries Inc, Enovis Corp, Essity AB, Ossur hf, Performance Health Holding Inc, Prime Medical Inc, and Zimmer Biomet Holdings Inc, among others. 

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com